Vital Health Podcast

Tim Scott: MFN Pricing, Venture Risk, and the Future of California Biotech

12 Feb 2026

Contributed by Lukas

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Tim Scott, President & CEO of Biocom California, a biopharma e...

Mark Rohrbaugh & Gwen O’Loughlin: Drug Patents, March-In Rights, and NIH Technology Transfer

29 Jan 2026

Contributed by Lukas

In this episode of the Vital Health Podcast, host Duane Schulthess examines how NIH-funded research fits into the U.S. innovation and IP ecosystem, an...

Oriana Ciani & Denis Lacombe: Overall Survival and Surrogate Endpoints in Early Oncology Approvals

21 Jan 2026

Contributed by Lukas

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with two experts on evidence standards for early oncology access at ISPOR Eu...

Anja Schiel & Nicholas Hedberg: Accelerated Approvals, Evidence Gaps, and Reimbursement Risk

14 Jan 2026

Contributed by Lukas

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with two experts on reimbursement-facing evidence questions for accelerated ...

Kathleen Grieve, Martina Garau, & Bettina Ryll: Accelerating Patient Access To Cancer Medicines In Europe

09 Jan 2026

Contributed by Lukas

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with three experts on accelerated patient access to cancer medicines at ISPO...

2025 US Policy Highlights - Inflation Reduction Act (IRA) Part 2

02 Jan 2026

Contributed by Lukas

In this special 2025 U.S. Policy Highlights edition of the Vital Health Podcast, we look back at our most important discussions on the Inflation Reduc...

2025 US Policy Highlights - Most Favored Nation (MFN)

26 Dec 2025

Contributed by Lukas

In this special 2025 U.S. Policy Highlights edition of the Vital Health Podcast, we look back at our most important discussions on Most Favored Nation...

2025 U.S. Policy Highlights - Inflation Reduction Act (IRA) Part 1

19 Dec 2025

Contributed by Lukas

In this special 2025 U.S. Policy Highlights edition of the Vital Health Podcast, we look back at our most important discussions on the Inflation Reduc...

Steffen Thirstrup & Richard Bergstrom: Evidence, Access, and Competitiveness in Europe

11 Dec 2025

Contributed by Lukas

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with two experts in European regulation and evidence of new medicines: Stef...

Malina Müller: Rethinking Accelerated Approvals in Europe

27 Nov 2025

Contributed by Lukas

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Dr. Malina Müller, Head of Health Economics at WifOR Institute, to...

VT's Grumpies Talk MFN

24 Oct 2025

Contributed by Lukas

In this episode of the Vital Health Podcast, host Duane Schulthess sits down with two Vital Transformation colleagues to explore key trends in drug pr...

Bettina Ryll, Kjetil Taskén & Anni Lepland: PRIME-ROSE & EU Joint Action

15 Oct 2025

Contributed by Lukas

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with three leaders advancing precision cancer medicine implementation in Eur...

John Murphy: Generics, Biosimilars, and U.S. Policy

08 Oct 2025

Contributed by Lukas

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with John Murphy, President and CEO of the Association for Accessible Medici...

Patrick Kelly: Inside the Generic Supply Chain Squeeze

01 Oct 2025

Contributed by Lukas

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Patrick Kelly, Chief Advocacy Officer at the Healthcare Distribution Al...

Lieven Annemans & Andreas Charalambous: Moving the Needle in EU Cancer Care

03 Sep 2025

Contributed by Lukas

In this Vital Health Podcast, host Duane Schulthess speaks with two leading European voices on oncology and health economics: Andreas Charalambous: ...

Kirsten Axelsen: Part D Shift, IRA Penalties, and Access Risks

27 Aug 2025

Contributed by Lukas

Kirsten Axelsen is an economist specializing in Medicare reimbursement, payer negotiations, and innovative reimbursement contracts. She’s a fell...

Best-of Edition: Pernille Weiss & Niklas Blomberg on EU Pharma Policy

21 Aug 2025

Contributed by Lukas

In this "Best-of" edition of the Vital Health Podcast, Duane Schulthess revisits two listener favorites on the future of medicines in Europe. Fir...

Henry Skinner: Fixing the Antibiotics Market & Confronting AMR

13 Aug 2025

Contributed by Lukas

In this Vital Health Podcast, host Duane Schulthess - joined by Joe Hammang, Vital Transformation's US Business Director - speaks with Henry Skinner (...

Best-of Edition: Peter Kolchinsky & John LaMattina on the IRA

06 Aug 2025

Contributed by Lukas

In this “Best of” edition, host Duane Schulthess revisits two landmark conversations on the long-term impact of the Inflation Reduction Ac...

Barbara McAneny, Rafael Fonseca, and Steve Potts: Protecting Patients Amid the IRA

30 Jul 2025

Contributed by Lukas

In this episode of the Vital Health Podcast, host Duane Schulthess convenes three leading voices from the 2025 BIO International Convention - prominen...

Sam Rasty, Steve Potts, and Joe Hammang: Policies, Patients, and the Biotech Narrative

17 Jul 2025

Contributed by Lukas

In this episode, Duane Schulthess is joined by Sam Rasty, Chief Business Officer at Sensorium Therapeutics, Steve Potts, Chair of the Drug Develo...

Ipsita Smolinski: Drug Pricing, R&D, & Global Policy

26 Jun 2025

Contributed by Lukas

In this episode, host Duane Schulthess sits down with Ipsita Smolinski, Founder and Managing Director of Capitol Street and faculty at Georgetown Univ...

Strengthening Biotech Ecosystems: Steve Potts & Robert Coughlin

18 Jun 2025

Contributed by Lukas

In this Vital Health Podcast episode, host Duane Schulthess sits down with Steve Potts, biopharma entrepreneur and chair of the Drug Development Counc...

Jocelyn Ulrich: PBMs, Policy Risk, and Biopharma’s Future

11 Jun 2025

Contributed by Lukas

In this Vital Health Podcast, host Duane Schulthess speaks with Jocelyn Ulrich, Vice President of Policy and Research at PhRMA, to discuss the far-rea...

Jenni Nordborg: Life Sciences Governance & EU Regulatory Alignment

22 May 2025

Contributed by Lukas

In this episode of the Vital Health Podcast, host Duane Schulthess sits down with Jenni Nordborg, Director of International Affairs at The Swedish Ass...

Donna Cryer: Advocacy, Drug Incentives & Research Crisis

12 May 2025

Contributed by Lukas

In this episode of the Vital Health Podcast, host Duane Schulthess sits down with patient advocate and Global Liver Institute founder Donna Cryer. The...

VT’s Grumpies Talk IRA with Virginia Acha

06 May 2025

Contributed by Lukas

In this special Grumpies episode, host Duane Schulthess, CEO of Vital Transformation, is joined by neuroscientist and US Business Director Joe Hammang...

Steve Usdin: Tariffs, Price Controls, & Inflation Reduction Act (IRA)

23 Apr 2025

Contributed by Lukas

In this episode, host Duane Schulthess sits down with Steve Usdin, Senior Washington Editor at BioCentury Publications since 1993 and one of the most ...

Expanding Oncology Treatments: PRIME-ROSE and the Future of Drug Repurposing

21 Feb 2025

Contributed by Lukas

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with two key voices driving the PRIME-ROSE initiative: Gro Live Fagereng, Pr...

Breaking Barriers: The Prime Rose Project and Off-Label Drug Innovations

18 Dec 2024

Contributed by Lukas

Join host Duane Schulthess on the Vital Health Podcast as he explores the groundbreaking Prime Rose Project, an initiative redefining the use of off-l...

Impact of the Inflation Reduction Act on Venture Capital in Life Sciences

11 Dec 2024

Contributed by Lukas

In this Vital Health Podcast, John Stanford, Executive Director of Incubate, discusses the impact of the Inflation Reduction Act (IRA) on venture capi...

Investing in Health: Pathways to a Well-being Economy and Smarter Healthcare Budgets

20 Nov 2024

Contributed by Lukas

In this insightful episode of the Vital Health Podcast, we dive deep into the economic and societal benefits of investing in healthcare. Our esteemed ...

Addressing Europe's Health Challenges: Innovation, Prevention, and Policy

06 Nov 2024

Contributed by Lukas

Join us at the Gastein Health Conference for an insightful conversation on Europe's healthcare challenges and innovations! Host Duane Schulthess sits ...

The Future of Biotech: Steve Potts on Innovation, Policy, and the Impact of the IRA

07 Oct 2024

Contributed by Lukas

In this episode of the Vital Health podcast, host Duane Schulthess sits down with Steve Potts, a seasoned entrepreneur and CEO of SLAM BioTherapeutics...

Revolutionizing Healthcare with Real-World Data

25 Sep 2024

Contributed by Lukas

In the latest episode of the Vital Health podcast, we delve into the future of healthcare with Blythe Adamson from Flatiron Health. Learn how Flatiron...

Exploring the Intersection of Intellectual Property and Biotech Innovation

18 Sep 2024

Contributed by Lukas

In the latest episode of the Vital Health podcast, we engage in a thought-provoking discussion with Hans Sauer, Deputy General Counsel for Intellectua...

Unlocking the Power of Genomic Data: NashBIO's Role in Healthcare Innovation

13 Sep 2024

Contributed by Lukas

In this episode of the Vital Health podcast, we dive deep into the world of genomic data and its transformative impact on healthcare. Join host Duane ...

MEP Pernille Weiss – Rapporteur of the EU GPL

04 Sep 2024

Contributed by Lukas

In this Vital Health Podcast, Duane Schulthess speaks to Pernille Weiss, a former Member of the European Parliament and the Rapporteur of the European...

Transforming Health Communications: Insights from Virginia Amann

22 Aug 2024

Contributed by Lukas

Join us at the International 2024 BIO conference as host Duane Schulthess sits down with Virginia Amann, CEO of the Entente Network. Discover how Virg...

Joe Panetta – Policy Impacts on California Biopharma

01 Aug 2024

Contributed by Lukas

With the continuing pressure placed upon the US biopharma sector from Washington DC, how is the California biopharma ecosystem, arguably the leading h...

Niklas Blomberg, Executive Director, EU Innovative Health Initiative

03 Jul 2024

Contributed by Lukas

In this Vital Health Podcast, recorded live at the 2024 Bio International Conference, host Duane Schulthess sits down with Niklas Blomberg, the Execut...

Congressman Michael Burgess – IRA and March-in Rights

19 Jun 2024

Contributed by Lukas

Congressman Michael Burgess is the Chair of the House Rules Committee and one of only 20 M.D.s currently serving in Congress. Before his election to t...

Kim Hawkins - Project Co-Lead of IMI’s Trials@Home

22 May 2024

Contributed by Lukas

Trials@Home is a €39 million, pan-European public private partnership of the EU’s Innovative Medicines Initiative, focused on defining the best pr...

Douglas Holtz-Eakin, “Indications are going to be deeply affected by the IRA”

01 May 2024

Contributed by Lukas

Douglas Holtz-Eakin was formerly a professor of economics at Syracuse University and served as the director of the Congressional Budget Office from 20...

John LaMattina – Drug Price Controls and IP Attacks Get Real

27 Mar 2024

Contributed by Lukas

John LaMattina was President of Pfizer Global Research and Development and ran an international team of over 13,000 scientists and professionals. He h...

Kate Hudson & Joseph P. Allen – The Fact Free Attacks on IP

21 Mar 2024

Contributed by Lukas

This podcast features Kate Hudson, the Associate Vice President and Counsel for Policy at the Association of American Universities, and Joseph P. Alle...

VT’s Grumpy Old Men – The Administration’s Threats to use March-In Rights

14 Mar 2024

Contributed by Lukas

On December 8, 2023, The Biden Administration under the National Institute of Standards and Technology (“NIST”) released a Draft Interagency Guida...

PRIME-ROSE: The EU’s DRUP Trial Champion

07 Feb 2024

Contributed by Lukas

With a six million EUR funding grant from the European Commission, the PRIME-ROSE project will implement, across Europe, a series of prospective, non-...

Peter Kolchinsky - "IRA's 9 Years Is Too Short"

17 Jan 2024

Contributed by Lukas

In this Vital Health Podcast, Duane Schulthess speaks with Peter Kolchinsky, Managing Partner at RA Capital Management. Peter has authored several cri...

Christian Schneider, CMO Biopharma Excellence

08 Nov 2023

Contributed by Lukas

Christian Schneider is the Chief Medical Officer of Biopharma Excellence, and was formerly the Chief Scientific Officer at the UK’s MHRA. He was the...

Bettina Ryll at the 2023 ESMO Conference

01 Nov 2023

Contributed by Lukas

On this Vital Health Podcast, Duane Schulthess has a conversation with Bettina Ryll, the founder of the Melanoma Patient Network Europe. Bettina is re...

Dan Leonard, Executive Director, We Work For Health

11 Oct 2023

Contributed by Lukas

Dan is the newly appointed Executive Director of We Work For Health, bringing more than two decades of experience in advocacy, policy, and public affa...

Cancer Drug Developer Dr. Steve Potts' Congressional Testimony on the IRA

27 Sep 2023

Contributed by Lukas

In this Vital Health Podcast, we’re speaking with Steve Potts before his congressional testimony for the U.S. House Committee on Energy and Commerce...

Amy Miller and the PhRMA Foundation Push the R&D Envelope

20 Sep 2023

Contributed by Lukas

In this vital health podcast, we’re speaking with Amy M. Miller, the recently appointed President of the PhRMA Foundation. Amy has held nonprofit le...

VT’s Grumpy Old Men on Price Controls and IP Attacks

13 Sep 2023

Contributed by Lukas

The U.S. Congress and Biden Administration’s attacks on IP and Drug Pricing continue unabated as the 2024 election approaches. In this Vital Health ...

Taking the Helm Mid Drug Pricing Maelstrom

06 Sep 2023

Contributed by Lukas

In this Vital Health Podcast, Duane Schulthess speaks with Rachel King, the Interim CEO of the Biotechnology Innovation Organization (BIO), who is ste...

Best-of Edition: Looking back on the COVID-19 outbreak part 2

24 Aug 2023

Contributed by Lukas

In this Best-Of edition of the Vital Health Podcast, we’re looking back on the outbreak of the COVID-19 pandemic and discussions we had with statis...

Best-of Edition: Looking back on the COVID-19 outbreak

10 Aug 2023

Contributed by Lukas

In this Best-Of edition of the Vital Health Podcast, we're looking back on the outbreak of the COVID-19 pandemic, and conversations with Epidemiologis...

CMS' Restrictions on Alzheimer's Drugs

01 Aug 2023

Contributed by Lukas

In this Vital Health Podcast, Duane Schulthess speaks with John Dwyer. John is a serial entrepreneur, having successfully built and sold two healthcar...

Biocom California Grapples with Regulatory Assaults on all Fronts

20 Jul 2023

Contributed by Lukas

With the Inflation Reduction Act now law, there are mounting concerns that its drug pricing revisions will have a huge negative impact on the Californ...

Amitabh Chandra - IRA’s potential impact on the US biopharma ecosystem

12 Jul 2023

Contributed by Lukas

Amitabh Chandra is the director of health policy research at the Harvard Kennedy School of Government, and a professor of business administration at H...

NJ’s Biopharma Sector in a Price Controlled World

06 Jul 2023

Contributed by Lukas

In this Vital Health Podcast, we speak with Debbie Hart, President & CEO of BioNJ about the direct impacts of the Inflation Reduction Act upon her...

IRA’s Impact on Orphan Therapies – David Meeker

29 Jun 2023

Contributed by Lukas

A Boston Success story, Rhythm Pharmaceuticals brought to market an innovative orphan therapy treating an extremely rare genetic disorder which causes...

Nick Shipley - IRA’s Impact on the Biopharma Ecosystem

23 Jun 2023

Contributed by Lukas

This Vital Health Podcast was recorded at the BIO international Conference on the afternoon of the release of Vital Transformation’s research study ...

Nikolai Brun - Improving Europe's Biopharma Legislation

31 May 2023

Contributed by Lukas

Nikolai Brun is a rare regulator who has rolled up his sleeves and successfully helped bring a therapy to market. He was part of a team at Genmab that...

EU Cost Effectiveness Models Threaten Vulnerable U.S. Patients

17 May 2023

Contributed by Lukas

The Quality Adjusted Life Year, or QALY, was invented at the UK’s University of York by Prof Alan Williams in the 1970s. Some currently engaged in t...

Andrew Roddam, CEO of Our Future Health

11 May 2023

Contributed by Lukas

Andrew Roddam is the CEO of Our Future Health, the UK’s largest ever health research programme. The objective of Our Future Health is to bring toget...

Attacks on Bayh-Dole Put University Research at Risk

04 May 2023

Contributed by Lukas

For the last several years in DC, a debate has raged as to the appropriate roles of industry, academia, and the NIH for R&D in the biopharma secto...

California Life Sciences’ Response to the Inflation Reduction Act

16 Mar 2023

Contributed by Lukas

Known for sunshine, Hollywood Movies, Mikey Mouse, and Silicon Valley, California has been at the center of global biotech for nearly half a century. ...

"Bayh–Dole Cannot be Used for Controlling Prices"

02 Mar 2023

Contributed by Lukas

On this Vital Health Podcast, we speak to Joseph Allen, the Executive Director of the Bayh-Dole Coalition. Joe served as a Senior Staff Member of form...

Price Controls put US Biopharma at Risk

16 Feb 2023

Contributed by Lukas

Vital Transformation’s Grumpy Old Men discuss their recently published research which found that 60% of FDA approved medicines from 2011- 2020 origi...

Patrick Kilbride - The Dangers of March-In Rights

02 Feb 2023

Contributed by Lukas

On October 7th, Health and Human Services Secretary Xavier Becerra said that the use of March-In Rights to control the pricing of medicines was not, “...

John LaMattina, Defending Pharma & Profits

25 Jan 2023

Contributed by Lukas

John LaMattina is the author of several highly respected books showcasing a deep insider's perspective of the biopharma industry. His latest book, "Ph...

Small Molecules Get Short Shrift, Jeff Jonker and the IRA

22 Dec 2022

Contributed by Lukas

With the passage of the Inflation Reduction Act (IRA), the US Government has fully embraced the idea of mandating price controls for therapies paid f...

The Accelerated Approval Pathway is Vital for Rare Diseases

08 Dec 2022

Contributed by Lukas

Proposed federal and state policies to restrict coverage and access to biomedical innovations approved through the FDA’s accelerated approval pathwa...

IRA's Impact on Biopharma Innovation with Amitabh Chandra

02 Dec 2022

Contributed by Lukas

With the US Inflation Reduction Act now law, many in Washington DC are saying that it’s provisions reducing pricing by $80 billion dollars annually ...

NovaQuest’s Devin Rosenthal on BioPharma Investing in a Post IRA World

11 Nov 2022

Contributed by Lukas

On this Vital Health Podcast, Duane Schulthess speaks with Devin Rosenthal, Vice President at NovaQuest Capital Management, who is responsible for the...

Hans Sauer is Sour on the WTO’s Waivers of mRNA IP

28 Oct 2022

Contributed by Lukas

On June 17th, a Rubicon of sorts was crossed in Geneva as The World Trade Organization (WTO) agreed to the compulsory licensing for COVID-19 vaccines....

NIH’s Impact on FDA Approvals is Statistically Zero, with Vital Transformation's Grumpy Old Men

30 Sep 2022

Contributed by Lukas

Our podcast features Vital Transformation’s Grumpy Old Men (Harry Bowen, Joseph Hammang, and Duane Schulthess) and their recently published peer re...

Paul Neureiter on European Innovation, US Legislation, and China’s Biopharmaceutical Growth

15 Sep 2022

Contributed by Lukas

The covid pandemic has brought into sharp focus the benefits as well as the challenges posed by the global supply chain related to the development of ...

CEOi’s John Dwyer on accelerated approvals, CMS, and Alzheimer’s Disease

08 Sep 2022

Contributed by Lukas

What do you do when you’ve been an entrepreneur, and have successfully built and sold two healthcare start-ups to 3M and Aetna? If you’re John Dwy...

SSR Health’s Richard Evans on Medicare Price Controls

10 Aug 2022

Contributed by Lukas

With the passage of the Inflation Reduction Act by the US Senate, the US is now on the cusp of implementing very aggressive drug pricing controls with...

Michele Oshman – Driving Innovation for the US’ Biotech State Associations

04 Aug 2022

Contributed by Lukas

Michele Oshman is Vice President of External Affairs of BIO, and the Executive Director of BIO’s Council of State Bioscience Associations (CSBA), ad...

John M. O'Brien’s Hot Takes on March-in, Co-Pays, PBMs, CMS, and Patient Access

16 Jul 2022

Contributed by Lukas

John Michael O'Brien was recently appointed as the president and Chief Executive Officer of the National Pharmaceutical Council (NPC), one of the key ...

Rutgers’ Gary Branning Untangles a PBM Web of Complexity

08 Jul 2022

Contributed by Lukas

On May 5th of this year, a very strange thing happened. For the first time in memory, the Pharmaceutical Benefit Managers, or PBMs, who act as the go-...

Joe Panetta Steers Biocom California’s Members Through Increasingly Stormy Seas

01 Jul 2022

Contributed by Lukas

 It seems every week we hear of another new proposal out of Washington DC to ‘fix’ drug pricing, and many of the companies that would be impacted...

Accelerated Approval Study Release - A Vital Pathway for Patients

22 Jun 2022

Contributed by Lukas

Recorded live at the 2022 BIO International Conference in San Diego, this podcast discusses the results of Vital Transformation's latest research stud...

Danny Seiden leads Arizona’s push against march-in rights

15 Jun 2022

Contributed by Lukas

With the Center for Medicare and Medicaid Services’ recent decision to limit access to Biogen’s Alzheimer’s treatment, and with drug...

Flagship Pioneering’s Tom Dilenge On Accelerated Approvals

21 Apr 2022

Contributed by Lukas

One of the brightest minds in DC, Tom Dilenge recently joined Flagship Pioneering, the highly respected bio platforms innovation company behind such g...

George Vradenburg, USAgainstAlzheimer's, and CMS' NCD

08 Apr 2022

Contributed by Lukas

George Vradenburg is the co-founder and chairman of USAgainstAlzheimer's, a patient advocacy organization founded in 2010, which has successfully work...

Sue Peschin - “CMS is in an untenable position” on Alzheimer’s disease

10 Mar 2022

Contributed by Lukas

When the Centers for Medicare and Medicaid Services (CMS) published its draft determination requiring further clinical trials in Alzheimer’s dis...

VT analyzed CMS' Alzheimer's disease draft guidance - it's REALLY bad

25 Feb 2022

Contributed by Lukas

The Centers for Medicare & Medicaid Services (CMS) recently released draft guidance that, in the future, proposes to only reimburse FDA approved t...

All Things Plasma Matter, Amy Efantis - CEO, Plasma Protein Therapeutics Association

14 Feb 2022

Contributed by Lukas

Most people think of the plasma sector as just another arm of biotechnology, but nothing could be further from the truth.  Relying primarily upon...

Joan Koerber-Walker and AZBio, Will Drug Pricing Kill a Rising Phoenix?

10 Feb 2022

Contributed by Lukas

Joan Koerber-Walker is President and CEO of the Arizona Bioindustry Association (AZBio), supporting one of the top emerging biotech clusters in the Un...

John Murphy, is Build Back Better Bad for Biotech?

16 Dec 2021

Contributed by Lukas

John Murphy is the Vice President of the Biotechnology Innovation Organization (BIO), the largest trade association in the world representing biotechn...

Miriam Sturkenboom & VAC4EU: Timing is everything

22 Oct 2021

Contributed by Lukas

Call it serendipity, ‘luck’, or being at the right place at the right time, but Miriam Sturkenboom led the IMI’s project Advance, which built a ...

NCATS’ Chris Austin - R&D from NIH, to Industry, through Approval

20 Jul 2021

Contributed by Lukas

After nearly two decades at the NIH and almost 10 years as founding director of the National Center for Advancing Translational Sciences (NCATS), Chri...

About the NIH, Industry, and the R&D Ecosystem, with Richard Moscicki, PhRMA

08 Jul 2021

Contributed by Lukas

Richard Moscicki is the Executive Vice President for Science and Regulatory Advocacy and the Chief Medical Officer at Pharmaceutical Research and Manu...

Jack Scannell on Big Pharma’s Big Drug Discovery Problem

17 Jun 2021

Contributed by Lukas

Jack Scannell is one of the world’s leading pharmaceutical industry analysts, as well as one of its most visionary. Jack caused a case of global pha...

Is U.S. reference pricing a fatal shot for biotech?

05 May 2021

Contributed by Lukas

Drug pricing is becoming a hot political issue in Washington DC, with polls showing widespread bipartisan support for congressional action to control ...